Samuel Bjork

Samuel is a Partner at Digitalis.

He serves as a director on the boards of Bonum Therapeutics, Elemental Machines, EpiBiologics, T-Therapeutics, and Terray Therapeutics. He has also served as a board director of PetMedix (acquired by Zoetis) and board observer of Good Therapeutics (acquired by Roche), Scout Bio, Nuvig Therapeutics, and Switch Therapeutics.

Prior to Digitalis, Samuel was a member of the healthcare and clean energy practices at the Boston Consulting Group. He received graduate degrees from Cambridge and Oxford University as a Marshall Scholar and an A.B. in Chemistry from Harvard University.